Purpose: To evaluate the ability of GDx with variable corneal compensator (VCC) compared to visual-evoked potentials (VEPs) and standard automated perimetry (SAP) in the detection of early optic nerve damage in patients with multiple sclerosis (MS). Methods: 46 eyes of 23 MS patients were included. Ten of them had a history of acute retrobulbar optic neuritis. A control group of 20 normal subjects was also included. All subjects underwent a complete ophthalmological examination and testing with SAP, GDx VCC and VEPs. Results: 19 eyes (41.3%) were abnormal with GDx VCC compared to 38 eyes (82.6%) with SAP and 31 (64.4%) with VEPs. In the optic neuritis group, 9 eyes (69.2%) had optic nerve pallor; SAP was abnormal in 8 of these eyes (61.5%) while VEPs and GDx VCC were abnormal in 6 eyes (46.1%). 2/20 eyes (10.0%) in the control group gave a false-positive abnormal result with SAP. GDx VCC and VEP were normal for all the eyes in the control group. Conclusions: GDx VCC is less able to detect early defects in MS patients compared to the currently used standard techniques of SAP and VEPs.

Keywords:
Multiple sclerosis glaucoma, Nerve fibre analysis, Optic neuritis
1.
Lycke J, Tollesson PO, Frisèn L: Asymptomatic visual loss in multiple sclerosis. J Neurol 2001;248:1079–1086.
2.
Ashwort B, Aspinall PA, Mitchell JD: Visual function in multiple sclerosis. Doc Ophthalmol 1990;73:209–224.
3.
Frisén L, Hoyt WF: Insidious atrophy of retinal nerve fibers in multiple sclerosis. Funduscopic identifications in patients with and without visual complaints. Arch Ophthalmol 1974;92:91–97.
4.
Sandberg- Wollheim M, Bynke H, Cronquist S: A long-term prospective study of optic neuritis: evaluation of risk factors. Ann Neurol 1990;27:386–393.
5.
Ulrich J, Groebke-Lorenz W: The optic nerve in multiple sclerosis. A morphological study with retrospective clinico-pathological correlations. Neuro-Ophthalmol 1983;3:149–159.
6.
Parisi V, Manni G, Spadaro M, Colacino G, Restuccia R, Marchi S, Bucci MG, Pierelli F: Correlation between morphological and functional impairment in multiple sclerosis patients. Invest Ophthalmol Vis Sci 1999;40:2520–2527.
7.
Lucci B, Viel R, Brusini P, Della Mea G: New trends in neuro-ophthalmological diagnosis of multiple sclerosis: computerized automated perimetry (in Italian). Riv Neurobiol 1991;37(3):111–117.
8.
Brusini P, Budai R, Dal Mas P, Della Mea G, Lucci B, Viel R: Subclinical centro-cecal field defects in multiple sclerosis; in Heijl A (ed): Perimetry Update 1988/89. Amsterdam, Kugler & Ghedini, 1989, pp 111–115.
9.
Henson DB, Chaudry S, Artes PH, Faragher E, Anson A: Response variability in the visual field: comparison of optic neuritis, glaucoma, ocular hypertension, and normal eyes. Invest Ophthalmol Vis Sci 2000;41:417–421.
10.
Keltner JL, Johnnson CA, Spurr JO, Beck RW, and the Optic Neuritis Study Group: Visual field profile of optic neuritis. One-year follow-up in the Optic Neuritis Treatment Trial. Arch Ophthalmol 1994;112:946–953.
11.
Sisto D, Trojano M, Vetrugno M, Trabucco T, Iliceto G, Sborgia C: Subclinical visual involvement in multiple sclerosis: a study by MRI, VEPs, frequency-doubling perimetry, standard perimetry, and contrast sensitivity. Invest Ophthalmol Vis Sci 2005;46:1264–1268.
12.
Paty DW, Oger JJF, Kastrukoff LF, Hashimoto SA, et al: MRI in the diagnosis of MS: a prospective study of comparison with clinical evaluation, evoked potentials, oligoclonal banding, and CT. Neurology 1988;38:180–185.
13.
Plant GT, Kermode AG, Turano G, et al: Symptomatic retrochiasmal lesion in multiple sclerosis: clinical features, visual evoked potentials and magnetic resonance imaging. Neurology 1992;42:68–76.
14.
Wing-Hong VL, Hei Mok K: Retinal nerve fiber layer measurement by nerve fiber analyzer in normal subjects and patients with glaucoma. Ophthalmology 1999;106:1006–1008.
15.
Lauande-Pimentel R, Carvalho R, Oliveira HC, Goncalves DC, Silva LM, Costa VP: Discrimination between normal and glaucomatous eyes with visual field and scanning laser polarimetry measurements. Br J Ophthalmol 2001;85:586–591.
16.
Steel DHW, Waldock A: Measurement of the retinal nerve fibre layer with scanning laser polarimetry in patients with previous demyelinating optic neuritis. J Neurol Neurosurg Psychiatry 1998;64:505–509.
17.
Banks MC, Robe-Collignon NJ, Rizzo JF, Pasquale LR: Scanning laser polarimetry of edematous and atrophic optic nerve heads. Arch Ophthalmol 2003;121:484–490.
18.
Meier FM, Bernasconi P, Sturmer J, Caubergh M-J, Landau K: Axonal loss from acute optic neuropathy documented by scanning laser polarimetry. Br J Ophthalmol 2002;86:285–287.
19.
Trip SA, Schlottmann PG, Jones SJ, Altmann DR, Garway-Heath DF, Thompson AJ, Plant GT, Miller DH: Retinal nerve fibre layer axonal loss and visual dysfunction in optic neuritis. Ann Neurol 2005;58:383–391.
20.
Fisher JB, Jacobs DA, Markowitz CE, et al: Relation of visual function to retinal nerve fiber layer thickness in multiple sclerosis. Ophthalmology 2006;113:324–332.
21.
Schlottmann PG, De Cilla S, Greenfield DS, Caprioli J, Garway-Heath DF: Relationship between visual field sensitivity and retinal nerve fibre layer thickness as measured by scanning laser polarimetry. Invest Ophthalmol Vis Sci 2004;45:1823–1829.
22.
Reus N, Lemij H: The relationship between standard automated perimetry and GDx VCC measurements. Invest Ophthalmol Vis Sci 2004;45:840–845.
23.
Monteiro MLR, Medeiros FA, Ostroscki MR: Quantitative analysis of axonal loss band atrophy of the optic nerve using scanning laser polarimetry. Br J Ophthalmol 2003;37:111–117.
© 2007 S. Karger AG, Basel
2007
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.